Looks like we just can't break past the 15,000 / 16,000 script wall and stay there.
Dilution is assured by the end of this year in order to pay Amarin Management their self-awarded compensations.
Funny how some harp that it is "the board" that awarded the compensation - yes formally it is - but we shouldn't be so naïve as to realize that these upper managers help each other out by sitting on each other's boards and granting each other outlandish compensation packages.
So much for any script bump from the withdrawal of competing products. Very frustrating to not see any ramp up on script growth given the torrent of supporting research papers. Any idea what Kowa is doing? Any hard data on insurance coverage/eligibility?